Literature summary for 3.5.4.B9 extracted from

Wang, Y.; Wu, S.; Zheng, S.; Wang, S.; Wali, A.; Ezhilarasan, R.; Sulman, E.P.; Koul, D.; Alfred Yung, W.K.
APOBEC3G acts as a therapeutic target in mesenchymal gliomas by sensitizing cells to radiation-induced cell death (2017), Oncotarget, 8, 54285-54296 .

Search for more literature for 3.5.4.B9

Application

Application	Comment	Organism
medicine	APOBEC3G mediated checkpoint activation through checkpoint kinase 2 (Chk2) is one of the critical regulatory mechanisms that underlies the preferential DNA damage checkpoint response and radioresistance of Glioma Initiating Cells. Thus, anti-APOBEC3G therapy may synergize with radiotherapy and other current treatments to overcome the therapeutic resistance of gliomas. APOBEC3G represents a potential molecular target for novel therapeutics that will improve the treatment outcome of glioma patients	Homo sapiens

Organism

Organism	UniProt	Comment	Textmining
Homo sapiens	Q9HC16	-	-

Source Tissue

Source Tissue	Comment	Organism	Textmining
mesenchymal glioma stem cell	APOBEC3G is preferentially expressed in mesenchymal gliomas	Homo sapiens	-

Synonyms

Synonyms	Comment	Organism
APOBEC3G	-	Homo sapiens

Use of this online version of BRENDA is free under the CC BY 4.0 license. See terms of use for full details.

Release 2023.1 (January 2023)